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COCHRANE REVIEWS
Cochrane Collaborative Review Group on Peripheral Vascular Diseases:
Review Abstracts
AbstractsIntroduction
Abstract: Surgery for deep-venous incompetenceThe following abstracts are part of an ongoing series
A. Abidia and S. C. Hardyof articles produced by the Cochrane Collaborative
Date of most recent substantive amendment:Review Group on Peripheral Vascular Diseases, which
20 December 1999is part of the Cochrane Collaboration. The reviews are
published in full on ‘‘The Cochrane Library’’, a quarterly
electronic journal available on CD-ROM and via the
Internet. The electronic format allows Cochrane re-
Background
views to accommodate new data as they become avail- Chronic deep-venous incompetence (DVI) is a trouble-
able, making the library a consistently up-to-date some condition presenting with a variable range of
source of information over time. distressing symptoms including recurrent ulcers, leg
pain and leg swelling. The underlying defect may
The abstracts appearing on the Cochrane Library be valvular incompetence, obstruction of large-calibre
are now presented in a different, simpler, less scientific veins, or a combination of the two.
format than the abstracts presented here to permit
greater accessibility to the public. However, the sub-
stance of both versions is the same. Review abstracts Objectives
on Cochrane reviews will be indexed on MEDLINE
To establish the effectiveness of various surgical pro-in the near future.
cedures in the treatment of deep-venous incompetence.
If you are interested in writing a Cochrane review
or contributing to the activities of the Cochrane Peri- Search Strategy
pheral Vascular Diseases Group please contact:
Randomised controlled trials of surgical treatment of
deep-venous incompetence were sought through com-Professor F. G. R. Fowkes,
puterised searches of EMBASE and MEDLINE, andCochrane Collaborative Review Group on Peripheral
by hand-searching relevant journals, using the searchVascular Diseases,
strategy described by the Cochrane Collaboration’sPublic Health Sciences,
Peripheral Vascular Disease Review Group. AdditionalUniversity of Edinburgh,
strategies used to identify studies included: searchingTeviot Place,
reference lists of identified studies; direct contact withEdinburgh EH8 9AG
principal investigators of identified trials; and directTel. +44 (0) 131 650 3220
contact with world experts in deep-venous surgery.Fax. +44 (0) 131 650 6904
Any comments or criticisms on these Cochrane re-
views/abstracts should be made through the com-
Selection Criteria
ments/criticisms facility on the Cochrane Library, or All randomised controlled trials of the surgical treat-
ment of patients with deep-venous incompetence.by contacting the group at the above address.
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Studies of participants undergoing valvuloplasty, ven- of 2 years. However, this single, small trial is not
sufficient to recommend the treatment to this subgroupous segmental transposition, venous segmental trans-
plantation or venous bypass surgery were eligible of patients with DVI.
No trials are available which investigated the resultsfor inclusion. Outcome measures were considered as
specified in the CEAP (clinical, etiologic, anatomic, of surgery for secondary valvular incompetence or the
obstructive form of DVI. Until more trials are available,pathophysiologic) classification and scoring system for
clinical outcome after surgery. Trials were selected by conventional conservative measures remain the treat-
ments of choice.AA and checked by SCH.
Abstract: Intravenous Naftidrofuryl For Critical LimbData Collection and Analysis
Ischaemia
F. B. Smith, A. W. Bradbury and F. G. R. FowkesOnly one trial met the inclusion criteria, none were
Date of most recent substantive amendment:excluded. The trial compared external valvuloplasty
5 January 2000using limited anterior plication (LAP) in combination
with ligature of incompetent superficial veins (Ligation
and LAP) against ligating incompetent superficial
veins only (Ligation only). Trial participants had prim-
Background
ary valvular incompetence with mild to moderate Peripheral arterial disease affects 5% of men and
symptoms but no venous ulcers. A variety of outcome women by late middle age. In approximately 25% of
measures were reported including ambulatory venous those affected the condition will progress to critical
pressure (AVP) and venous refill time (VRT). The limb ischaemia (rest pain, ulceration and gangrene)
reviewers extracted the data independently. within 5 years. The vasoactive drug naftidrofuryl is a
serotononergic receptor antagonist that may be bene-
ficial in the treatment of severe lower-limb disease
such as critical limb ischaemia.Main Results
Ligation and LAP produced significant improvement Objectives
in AVP: the mean difference between the Ligation and
To determine whether intravenous administration ofLAP group and the Ligation only group was -15
the vasoactive drug, naftidrofuryl, is effective in al-Torr (weighted mean difference (WMD) -20.9, -9.0,
leviating symptoms and reducing progression of dis-confidence interval (CI) 95% fixed) at 1 year and -15
ease in patients with critical limb ischaemia.Torr (WMD -21, -8.9, 95% CI fixed) at 2 years.
In contrast, there was no statistically significant
improvement in VRT, the mean difference between
the groups at one year was 2 s (WMD -2.7, 6.7; 95% Search Strategy
CI fixed) and at 2 years was 4 s (WMD -0.7, 8.7; 95%
CI fixed). Randomised controlled trials of intravenous naf-
Furthermore, the AVP values after surgery remained tidrofuryl for critical limb ischaemia were sought
relatively high. Nine out of 11 valves repaired re- through computerised searches of EMBASE and MED-
mained competent after 2 years of follow up. No LINE, and by hand-searching relevant journals, using
complications occurred. The overall mean score for the search strategy described by the Cochrane Col-
clinical outcome was +2 (moderate improvement) in laboration’s Peripheral Vascular Disease Review
the Ligation and LAP group. This compared with +1 Group. In addition, reference lists from relevant papers
(mild improvement) in the ligation-only group. were examined, and further publications sought
through contact with pharmaceutical companies.
Reviewers’ Conclusions
Selection Criteria
Ligation and LAP produced a moderate improvement
for patients with mild to moderate DVI secondary to All randomised controlled trials of critical limb isch-
aemia in which patients were randomly allocated toprimary valvular incompetence, in a follow-up period
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intravenous naftidrofuryl or control (either phar- analysis not possible) and analgesic consumption
(WMD -0.42; 95% CI -1.19, 0.35), but the effect wasmacological, inert placebo or conservative therapy)
were included. Trials including patients with in- statistically non-significant. Similarly, improvement in
rest pain or skin necrosis occurred with naftidrofuryl,termittent claudication were not eligible for inclusion.
Trials were selected by one reviewer and checked but these effects were also not significant. The effect
on mean ankle systolic pressure was inconclusive.independently.
Data Collection and Analysis
Fifteen trials were identified, but eight were excluded
Reviewers’ Conclusions
Based on the results of these trials, it cannot be con-because of poor methodology. The seven remaining
firmed that intravenous naftidrofuryl is effective intrials involved a total of 229 participants from five
the treatment of patients with critical limb ischaemia.different countries. The following outcomes were re-
However, these results are based on trials of, generally,ported: pain reduction, rest pain/necrosis, progression
low methodological quality, with variable methods,of disease in terms of incidence of surgical re-
small numbers of participants, and extremely shortconstruction/amputation, mortality and side-effects.
durations of treatment. In addition, the wide range ofOn extraction of the data, odds ratios and weighted
endpoints employed effectively precluded any mean-mean differences were estimated where appropriate.
ingful pooling of the results.
Intravenous naftidrofuryl was withdrawn as a treat-
ment for peripheral arterial disease in 1995 because ofMain Results
reported side-effects.
Treatment with naftidrofuryl tended to show reduction
of pain evaluated by both analogue score (where meta-
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